News

GSK's blood cancer drug fails to secure US FDA advisers' support
The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...
GSK blood cancer drug fails to win backing of key US regulatory panel
GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer drug, putting its ...
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...
GSK's blood cancer drug gets EU approval
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
Reuters2y
GSK's blood cancer drug fails main goal of trial, shares fall
Data calls into question existing drug approval -analysts GSK in talks with health authorities, other trials continuing Shares fall 3% Nov 7 (Reuters) - GSK's (GSK.L), opens new tab blood cancer ...
Benzinga.com4y
GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
GlaxoSmithKline plc GSK announced Wednesday the United States Food and Drug Administration had approved its cancer drug aimed at treating refractory multiple myeloma in adults. The monotherapy ...
GEN - Genetic Engineering and Biotechnology News1h
GSK, Hengrui Focus on Cancer, Respiratory Diseases, I&I in Up-to-$12.5B Collaboration
GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...